gp130 Small-Molecule Modulators for Improved Transdermal Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations for transdermal administration of small molecules targeting gp130 signaling pathways face challenges due to high hydrophobicity, leading to poor solubility and efficacy, necessitating improved compounds with enhanced physicochemical properties for effective treatment of inflammatory and degenerative disorders.
Innovation Solution
Development of small molecule modulators with structures defined by various Formulae (I, X-I, II, III, IV) that include optionally substituted cycloalkyl, heterocyclyl, heteroaryl, or aryl groups, designed to modulate gp130 signaling pathways and improve solubility and efficacy for transdermal delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecules with high hydrophobicity are used to target gp130 signaling pathways, then they can effectively bind to the target receptors, but they exhibit poor solubility and reduced efficacy for transdermal delivery
Solution Approach 1:
The patent applies parameter changes by systematically modifying the physicochemical properties of small molecule compounds through structural optimization. Specific chemical modifications were made to reduce hydrophobicity while maintaining target binding affinity, thereby improving solubility and transdermal delivery characteristics without completely sacrificing gp130 interaction capability
Solution Approach 2:
The patent employs composite material principles by developing formulations that combine the small molecule modulators with excipients and delivery vehicles. These composite formulations enhance the solubility and stability of the hydrophobic compounds while enabling effective transdermal delivery through optimized composition ratios and delivery system architecture
2Object-affected harmful factors
If small molecule modulators are administered topically to treat cutaneous disorders, then adverse side effects are minimized, but high hydrophobicity prevents effective transdermal penetration
Solution Approach 1:
The patent modifies molecular parameters such as logP (partition coefficient), molecular weight, and hydrogen bonding capacity to optimize transdermal penetration. These parameter adjustments reduce hydrophobicity barriers while maintaining the therapeutic advantage of localized topical action, enabling effective skin penetration without significant systemic absorption
Solution Approach 2:
The patent introduces formulation intermediaries such as penetration enhancers, surfactants, and delivery vehicles that facilitate transdermal transport of the hydrophobic modulators. These intermediaries create a bridge between the hydrophobic drug molecules and the aqueous environment of the skin, enabling effective delivery while maintaining the benefits of topical administration
3Ease of operation
If existing formulations are used for transdermal administration, then they provide a route for localized treatment, but poor solubility of hydrophobic compounds reduces treatment efficacy
Solution Approach 1:
The patent develops composite formulations incorporating solubilizing agents, cyclodextrins, lipid vehicles, or micellar systems that enhance the solubility of hydrophobic small molecule modulators. These composite systems maintain the advantages of transdermal administration while ensuring sufficient drug dissolution and bioavailability at the target site for effective treatment
Solution Approach 2:
The patent optimizes formulation parameters including pH, ionic strength, surfactant concentration, and vehicle composition to maximize the solubility and stability of the small molecule modulators. These parameter adjustments ensure that the compounds remain in solution at therapeutic concentrations throughout the transdermal delivery process, maintaining treatment efficacy
Data Source
AI summary
Disclosed herein are small molecule compounds, compositions, formulations, and methods of modulating gpl30. Compounds, compositions, and formulations described herein are capable of modulating pro-inflammatory, fibrotic and/or regenerative responses. The disclosure also provides methods for treating or ameliorating disease, disorders and conditions associated with gp130 activity, particularly those associated with inflammatory and degenerative disorders, or combination thereof.